Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
9 participants
OBSERVATIONAL
2017-07-31
2019-01-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Long-term Follow-up of HIV Infected Patients Identified During Early Infection
NCT00086372
A Comparison of HIV-Infected Patients With and Without Opportunistic (AIDS-Related) Infection
NCT00005572
Analysis of HIV-1 Replication During Antiretroviral Therapy
NCT00767312
Establish and Characterize an Acute HIV Infection Cohort in a High Risk Population
NCT00796146
HIV Persistence in Lymph Node and Peripheral Blood
NCT03426189
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Immune Controllers
Patients with very low or undetectable levels of viremia without treatment
No interventions assigned to this group
Acute Infection
Early infection, i.e. within 2 weeks of infection
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Signed Informed Consent Form
3. Age at least 18 years old
4. Immune controllers, two types: "Elite suppressors" (HIV-positive with any three consecutive plasma HIV-1 RNA PCR undetectable while off treatment) or "viremic suppressors" (HIV-positive with any three consecutive HIV-1 RNA PCR \<3000 while off treatment).
5. Acutely infected subjects:
Persons identified to have a negative HIV antibody response (ELISA) but positive detection of HIV-1 in the blood (RT-PCR) or individuals who have evidence of a recent (past 30 days) HIV negative result along with a current HIV positive result.
Exclusion Criteria
2. Pregnant.
3. Inability to provide informed consent.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of California, Los Angeles
OTHER
AIDS Healthcare Foundation
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Otto O Yang, MD
Role: STUDY_DIRECTOR
Scientific Director
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
AIDS Healthcare Foundation - Public Health Division
Los Angeles, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AHF 03
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.